Delivery Order SPE2DB22D3501-SPE2DB25FTY90

Award Date 12/30/24
Potential Completion Date 1/22/25
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,963.40 delivery order contract is for REVLIMID 5 MG CAPSULE 28S and has a completion date of January 7, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC). The contract is valued at $89,155.06 and covers the delivery of REVLIMID 10 MG CAPSULE 100S, a specialty medication. The award has an ultimate completion date of December 16, 2024. Amerisourcebergen holds a large $999,999,999 IDC with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $74,890.20 firm fixed-price delivery order is for the supply of 4,566,494,412 units of the drug REVLIMID 10 MG CAPSULE 28S. The contract has an ultimate completion date of December 11, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $178,310.12, is a delivery order for the supply of 10 mg Revlimid capsules. The contract has a firm fixed-price pricing type and an ultimate completion date of December 5, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $74,890.20, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of January 24, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,722.57 firm-fixed-price delivery order is for the supply of REVLIMID 25 MG CAPSULE 21S, a specialty pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 20 MG CAPSULE 100S. The award, valued at $89,155.06, has an ultimate completion date of October 8, 2024. AmerisourceBergen holds multiple Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for a comprehensive range of medical commodities. This...
This federal contract award is for the delivery of REVLIMID 15 mg capsules to the Defense Logistics Agency (DLA). The $89,155.06 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $89,155.06 and runs through November 25, 2024. There is no set-aside designation, indicating this was an open competition. Amerisourcebergen also holds a $999,999,999 Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm fixed-price contract is for the supply of REVLIMID 25 MG CAPSULE 100S, a specialty medication, to support military healthcare programs. The contract has an ultimate completion date of January 10, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award valued at $178,310.12 from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of REVLIMID 10 MG CAPSULE 100S, a prescription medication. The contract is a firm fixed-price agreement with a period of performance through January 24, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a significant...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FTY90
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,963.40, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 5 MG CAPSULE 28S. The contract has an ultimate completion date of January 22, 2025.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award was not designated with any set-aside requirements, indicating open competition.

Generated 3/31/25, 9:33 AM